{"id":"NCT04072575","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Paliperidone Palmitate 6-Month Formulation","officialTitle":"Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-19","primaryCompletion":"2022-05-03","completion":"2022-05-03","firstPosted":"2019-08-28","resultsPosted":"2023-05-31","lastUpdate":"2025-04-29"},"enrollment":178,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"PP6M injection Dose 1","otherNames":["R092670"]},{"type":"DRUG","name":"PP6M injection Dose 2","otherNames":["R092670"]}],"arms":[{"label":"Paliperidone Palmitate 6 month(PP6M)","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to assess the long-term safety and tolerability of paliperidone 6-month PP6M (Dose 1 or Dose 2 \\[milligram\\] mg eq.) and to provide access to PP6M in participants with schizophrenia completing the R092670PSY3015 study without relapse.","primaryOutcome":{"measure":"Number of Participants With Relapse","timeFrame":"Up to Day 730","effectByArm":[{"arm":"Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":30,"countries":["Argentina","Hong Kong","Italy","Poland","Russia","Ukraine"]},"refs":{"pmids":["39971605","38300235","37480362"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":178},"commonTop":["Headache","Blood Prolactin Increased","Hyperprolactinaemia","Diarrhoea","Nasopharyngitis"]}}